Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
underway; the program targets an orphan-size, treatment-naïve disease with no FDA-approved therapies and will use refined endpoints (IGA 0/1 with two-point reduction) after a 72-patient Phase 2b stepping into an ~270-patient Phase 3. Batoclimab failed to meet its Phase 3 TED primary endpoint , leading Immunovant to de-emphasize batoclimab in TED and shift focus to IMVT-1402 ; company commentary noted better outcomes with deeper IgG suppression and a small hyperthyroid subset showed promising IgG reductions and responder rates. Interested in Immunovant, Inc.? Here are five stocks we like better. Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint. Brepocitinib expands into lichen planopilaris Matt Gline, CEO of Roivant Sciences, said the companies are m
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM [Yahoo! Finance]Yahoo! Finance
- Immunovant shares plunge after phase 3 trials fails to meet primary endpoint [Yahoo! Finance]Yahoo! Finance
- Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) [Yahoo! Finance]Yahoo! Finance
- Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) [Yahoo! Finance]Yahoo! Finance
- Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)GlobeNewswire
IMVT
Earnings
- 2/6/26 - Beat
IMVT
Sec Filings
- 4/3/26 - Form 4
- 3/20/26 - Form 4
- 2/27/26 - Form 4
- IMVT's page on the SEC website